Antihyperlipidemic Drugs Market Growth, Demand and Challenges of the Key Industry Players 2024-32

1
Global Antihyperlipidemic Drugs Market Research
and Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Antihyperlipidemic Drugs Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2024-2032," the global
  antihyperlipidemic drugs market size reached US
  12.6 Billion in 2023.
• Antihyperlipidemic drugs help in lowering blood
  lipid levels, including cholesterol. These
  medications are also known as hypolipidemic or
  lipid-lowering drugs in reference to their main
  physiological effects. They can be taken along
  with different medicines to lower cholesterol and
  reduce the risk of developing certain diseases.
• Some commonly available antihyperlipidemic drugs
  include cholesterol absorption inhibitors, fibric
  acid derivatives, statins, antihyperlipidemic
  combinations, bile acid sequestrants, and PCSK9
  inhibitors. These drugs can prevent absorption,
  facilitate the elimination of more lipids in
  feces, and increase good cholesterol levels to
  lower bad cholesterol. At present,
  antihyperlipidemic drugs are available in
  different classes across the globe, which can be
  given depending on the patients underlying
  disease, cholesterol profile, and other factors.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/antihyperlipidemic-drug
  s-market/requestsample

4
Report Description

• Global Antihyperlipidemic Drugs Market Trends
• The rising prevalence of hyperlipidemia due to
  the high consumption of fatty foods and nicotine
  addiction represents the primary factor driving
  the market growth. Moreover, hyperlipidemia
  increases the risk of developing coronary artery
  disease (CAD), which is a leading cause of death
  among adults. In line with this, the escalating
  demand for antihyperlipidemic drugs to improve
  the low levels of high-density lipoprotein (HDL)
  cholesterol while reducing the high levels of
  low-density lipoprotein (LDL) cholesterol and
  triglycerides are positively influencing the
  market growth. Additionally, antihyperlipidemic
  drugs are used to treat high cholesterol levels
  and various lipid disorders in children. Along
  with this, the rising product demand to reduce
  hospitalization rates and premature deaths due to
  the increase in the number of genetic and
  acquired disorders of lipid and lipoprotein
  metabolism among the pediatric population has
  catalyzed market growth. Furthermore, several key
  players are developing, synthesizing, and
  evaluating a variety of new molecules for these
  drugs, thereby contributing to market growth.
  Other factors, including the rising prevalence of
  sedentary lifestyles, increasing incidences of
  cardiovascular disorders, surging approval of new
  and advanced drugs, and expanding geriatric
  population, are also anticipated to create a
  positive market outlook.
• Looking forward, IMARC Group expects the market
  value to reach US 18.2 Billion by 2032,
  expanding at a CAGR of 4.1 during 2024-2032.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/antihyperlipidemic-drug
  s-market

5
Report Segmentation

• Breakup by Drug Class
• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• PCSK9 Inhibitors
• Combination
• Others
• Breakup by Route of Administration
• Oral
• Intravenous
• Breakup by Distribution Channel
• Hospital Pharmacies

6
Report Segmentation

• Retail Stores
• Online Retailers
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Amgen Inc.
• AstraZeneca plc
• Daiichi Sankyo Company Limited
• Merck Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

8
Key Questions Answered in the Report
9
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Antihyperlipidemic
  Drugs Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Drug Class
• 6.1 Statins
• 6.1.1 Market Trends
• 6.1.2 Market Forecast
• 6.2 Bile Acid Sequestrants
• 6.2.1 Market Trends
• 6.2.2 Market Forecast
• 6.3 Cholesterol Absorption Inhibitors
• 6.3.1 Market Trends
• 6.3.2 Market Forecast       

10
Table of Contents

• 6.4 Fibric Acid Derivatives
• 6.4.1 Market Trends
• 6.4.2 Market Forecast
• 6.5 PCSK9 Inhibitors
• 6.5.1 Market Trends
• 6.5.2 Market Forecast
• 6.6 Combination
• 6.6.1 Market Trends
• 6.6.2 Market Forecast
• 6.7 Others
• 6.7.1 Market Trends
• 6.7.2 Market Forecast
• 7 Market Breakup by Route of Administration
• 7.1 Oral
• 7.1.1 Market Trends
• 7.1.2 Market Forecast
• 7.2 Intravenous
• 7.2.1 Market Trends
• 7.2.2 Market Forecast

11
Partial List of Clients
12
Partial List of Clients
13
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

14
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us